teaser
Arpida Ltd announced today its financial results for the year ending 31 December 2008.
2008 Key events
- Setback in regulatory process for intravenous iclaprim in US
- Restructuring and focus on iclaprim
- Top-line results of “intravenous-to-oral” Phase II trial with oral iclaprim
- Leadership change
- Share placin
2009 Priorities
- Finalise restructuring
- Design a roadmap for approval of intravenous iclaprim
- Consider and develop strategic options
With cash and financial investments of CHF38.7 million Dr Jürgen Raths, President and CEO, commented: “The negative FDA response of last January was a serious blow to our company and all of its stakeholders. The steps we have announced and executed, though painful, were unavoidable. We are currently pursuing several strategies to maximise shareholder value. This includes partnering, mergers and acquisitions as well as the disposal of certain assets as we do not have the money nor the time required to further develop iclaprim on our own.”
CFO Harry Welten, MBA, added: “Our cash balance at year-end 2008 was in line with our earlier guidance. We maintain our forecast that cash and financial investments will amount to approximately CHF 17 million at year-end 2009.”
